Volume 21, 2017

Sign On

Volume 21, 2017 CD
Six back issues from 2017 on one convenient CD.

Permanent storage and easy retrieval of IJPC articles and formulations.

Print journal articles in color from the PDF file for your marketing needs.
Eliminate long searches through past issues for formulations, compatibility studies, standard operating procedures, marketing ideas, and literature reviews.

Only $95 per CD

This CD contains the following articles listed by volume, issue and page number:


Issues Included
Volume/Issue	Date	Title
Vol. 21 No. 1	January/February 2017	Volume 21, Number 1
Vol. 21 No. 2	March/April 2017	Volume 21, Number 2
Vol. 21 No. 3	May/June 2017	Volume 21, Number 3
Vol. 21 No. 4	July/August 2017	Volume 21, Number 4
Vol. 21 No. 5	September/October 2017	Volume 21, Number 5
Vol. 21 No. 6	November/December 2017	Volume 21, Number 6

Volume 21, 2017 CD ARTICLES

Title (Click for Details)	Vol/Issue	Page

Volume 21, 2017 CD ARTICLES
PreScription: Compounding Pharmacy Issues for 2017	Vol. 21 No. 1	4
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 3	Vol. 21 No. 1	6
When to Compound Medications for Veterinary Patients	Vol. 21 No. 1	19
Case Report: Diabetic Foot Ulcer Infection Treated with Topical Compounded Medications	Vol. 21 No. 1	22
Why You Should Become an International Academy of Compounding Pharmacists Member	Vol. 21 No. 1	28
Analytic Methods Used in Quality Control in a Compounding Pharmacy	Vol. 21 No. 1	31
Basics of Compounding with Dilutions and Concentrates	Vol. 21 No. 1	39
Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms	Vol. 21 No. 1	47
Calculations	Vol. 21 No. 1	58
Clindamycin 10-mg/mL Oral Suspension	Vol. 21 No. 1	60
Diazoxide 10-mg/mL Oral Suspension	Vol. 21 No. 1	61
Infliximab 1% Ophthalmic Solution	Vol. 21 No. 1	62
Nifedipine 0.5% Rectal Ointment	Vol. 21 No. 1	63
Tetracaine Hydrochloride 0.5% Ophthalmic Solution	Vol. 21 No. 1	64
Zonisamide 10-mg/mL Oral Suspension	Vol. 21 No. 1	65
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate	Vol. 21 No. 1	66
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride	Vol. 21 No. 1	76
A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding	Vol. 21 No. 1	83
PreScription: Whatever Happened to Common Sense?	Vol. 21 No. 2	92
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies	Vol. 21 No. 2	95
Restructuring the Art of Health by Pharmacists: Formulation Designs with Oral Vehicles--Teaching Pharmacy Students	Vol. 21 No. 2	105
Consultation for Human, Veterinary, and Compounded Medications	Vol. 21 No. 2	111
The International Academy of Compounding Pharmacists Introduces a New President	Vol. 21 No. 2	116
Quality Control: (Material) Safety Data Sheets	Vol. 21 No. 2	118
Basics of Compounding: 3D Printing--Pharmacy Applications, Part 1	Vol. 21 No. 2	127
Accuracy Considerations in Sterile Compounding	Vol. 21 No. 2	133
Calculations	Vol. 21 No. 2	144
Azathioprine 10-mg/mL Oral Suspension	Vol. 21 No. 2	146
Candesartan Cilexetil 8 mg Liquid-Filled Capsules	Vol. 21 No. 2	147
Furosemide 10-mg/mL Oral Suspension	Vol. 21 No. 2	148
Ketoconazole 20-mg/mL Oral Suspension	Vol. 21 No. 2	149
Stability of Alprostadil in 0.9% Sodium Chloride Stored in Polyvinyl Chloride Containers	Vol. 21 No. 2	150
Stability of Two Antifungal Agents, Fluconazole and Miconazole, Compounded in HUMCO RECURA Topical Cream to Determine Beyond-Use Date	Vol. 21 No. 2	154
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions	Vol. 21 No. 2	160
Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs	Vol. 21 No. 2	164
Suspensions as a Valuable Alternative to Extemporaneously Compounded Capsules	Vol. 21 No. 2	171
PreScription: United States Pharmacopeia Chapter <800> Comments and Alternatives	Vol. 21 No. 3	180
Adventures in the Environmental World and Environmental Microbiology Sampling of Air for Pharmaceutical Sterile Compounding	Vol. 21 No. 3	182
Microbiologic Testing for 503A Sterile-Compounding Pharmacies	Vol. 21 No. 3	193
Management of Psoriasis with a XemaTop Topical Compounded Formula: A Case Report	Vol. 21 No. 3	205
International Academy of Compounding Pharmacists Legislative/Regulatory Update	Vol. 21 No. 3	212
Basics of Compounding: 3D Printing--Pharmacy Applications, Part 2	Vol. 21 No. 3	215
Basics of Sterile Compounding: Manipulating Peptides and Proteins	Vol. 21 No. 3	223
Calculations	Vol. 21 No. 3	230
Candesartan Cilexetil 0.1-mg/mL to 2.0-mg/mL Oral Suspension	Vol. 21 No. 3	232
Ketoconazole 20-mg/mL in SyrSpend SF pH4 Oral Suspension	Vol. 21 No. 3	233
Ketoprofen 10%, Baclofen 2%, Cyclobenzaprine Hydrochloride 2%, Lidocaine 2% in Lipopen Ultra Cream Base	Vol. 21 No. 3	234
Meloxicam 1% Topical Gel	Vol. 21 No. 3	235
Ofloxacin 0.3% Ophthalmic Solution	Vol. 21 No. 3	236
PVP Iodine 10% Antiseptic Cream	Vol. 21 No. 3	237
Tri-Est, Progesterone, and Testosterone in Versatile, Phytobase, Fitaline, and HRT Supreme Cream Bases	Vol. 21 No. 3	238
Trimethoprim 10-mg/mL Oral Suspension	Vol. 21 No. 3	239
Updated Stability Data for Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSpend SF and Minoxidil in Espumil	Vol. 21 No. 3	240
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats	Vol. 21 No. 3	242
Warfarin Personalized Dosage: Re-compounding for a More Suitable Therapy and Better Compliance	Vol. 21 No. 3	247
Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes	Vol. 21 No. 3	251
Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions	Vol. 21 No. 3	255
PreScription: Just Think About It!	Vol. 21 No. 4	268
Change Is In the Air: What You Need to Know About Pharmacy Ventilation Under United States Pharmacopeia <800>	Vol. 21 No. 4	271
Component Selection for Sterile Compounding	Vol. 21 No. 4	277
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas	Vol. 21 No. 4	282
The International Academy of Compounding Pharmacists Applauds the Leadership of Congressmen Griffith and Cuellar in Introducing Bill HR 2871	Vol. 21 No. 4	290
Basics of Compounding: 3D Printing: Pharmacy Applications, Part 3: Compounding, Formulation Considerations, and the Future	Vol. 21 No. 4	293
Basics of Sterile Compounding: Excipients Used in Injections	Vol. 21 No. 4	301
Calculations	Vol. 21 No. 4	310
Betamethasone 0.1% and Neomycin 0.6% Gel-Cream	Vol. 21 No. 4	312
Castor Oil 50% in Modified Pluronic Lecithin Organogel Gel	Vol. 21 No. 4	313
Copper Sulfate, Magnesium Sulfate, Phenylephrine, and Guaifenesin Pluronic Lecithin Organogel	Vol. 21 No. 4	314
Disopyramide 100-mg Capsules	Vol. 21 No. 4	315
Ferrous Sulfate 30-mg Fe/mL Oral Drops	Vol. 21 No. 4	316
Reteplase Injection	Vol. 21 No. 4	317
Sertraline Hydrochloride 10-mg/mL Oral Suspension	Vol. 21 No. 4	318
Tacrolimus 0.06% Ophthalmic Drops	Vol. 21 No. 4	319
Torsemide 10-mg/mL Injection	Vol. 21 No. 4	320
Tranilast 8% Pluronic Lecithin Organogel Gel	Vol. 21 No. 4	321
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)	Vol. 21 No. 4	322
Compounded Levofloxacin Triple Therapy is Safe and Effective for Refractory Helicobacter pylori	Vol. 21 No. 4	330
Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt	Vol. 21 No. 4	334
Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4	Vol. 21 No. 4	339
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia	Vol. 21 No. 4	347
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs	Vol. 21 No. 5	356
Compounding Opportunities in Urology	Vol. 21 No. 5	358
Child-safety Containers/Devices and Compounding	Vol. 21 No. 5	364
Documentation: Records and Reports	Vol. 21 No. 5	373
IACP Legislative/Regulatory Update	Vol. 21 No. 5	382
Quality Control: Bar Codes and Bar Code Scanners for Unit-Dose Medications in a Healthcare Setting	Vol. 21 No. 5	384
Basics of Compounding: 3D Printing--Pharmacy Applications: Geometric Shape Effects on 3D Printing	Vol. 21 No. 5	388
Basics of Sterile Compounding: Particulate Matter	Vol. 21 No. 5	395
Calculations	Vol. 21 No. 5	406
Acetylcysteine Solutions for Inhalation	Vol. 21 No. 5	408
Carbamazepine 25-mg/mL in SyrSPend SF pH4 Oral Suspension	Vol. 21 No. 5	409
Etoposide 20-mg/mL Injection	Vol. 21 No. 5	410
Fentanyl Citrate 50-mcg/mL Injection	Vol. 21 No. 5	411
Fluoxymesterone 10-mg Capsules	Vol. 21 No. 5	412
Ioversol Injection	Vol. 21 No. 5	413
Levocarnitine 100-mg/mL Oral Solution	Vol. 21 No. 5	414
Peritoneal Dialysis Solution with 1.5%, 2.5%, or 4.25% Dextrose	Vol. 21 No. 5	415
Tacrolimus 0.3-mg/mL Ophthalmic Solution	Vol. 21 No. 5	416
Vancomycin 50 mg/mL in Oral Syrup Suspension	Vol. 21 No. 5	417
Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3)	Vol. 21 No. 5	418
Stability of Dalteparin 1,000 Unit/mL in 0.9% Sodium Chloride for Injection in Polypropylene Syringes	Vol. 21 No. 5	426
Physicochemical Stability of an Oral Suspension of Trimethoprim 20 mg/mL in Combination with Sulfadiazine 200 mg/mL in PCCA Base SuspendIt	Vol. 21 No. 5	430
Stability of Dexmedetomidine in 0.9% Sodium Chloride in Two Types of Intravenous Infusion Bags	Vol. 21 No. 5	436
PreScription: Issues with the NAMS 2017 Hormone Therapy Position Statement	Vol. 21 No. 6	444
Feline Transdermal Formulation Considerations	Vol. 21 No. 6	446
Orodispersible Films for Compounding Pharmacies	Vol. 21 No. 6	454
Features of Pharmaceutical Compounding in the Republic of Tajikistan	Vol. 21 No. 6	463
Join the Partnership for Personalized Prescriptions (P3) Advocacy Effort!	Vol. 21 No. 6	468
Basics of Compounding: Hot Melt Extrusion	Vol. 21 No. 6	471
Basics of Compounding: Compounding Irrigation Solutions for Sterile and Nonsterile Preparations	Vol. 21 No. 6	481
Calculations	Vol. 21 No. 6	488
Amitriptyline 20 mg/mL in OraPlus:OraSweet Suspension	Vol. 21 No. 6	490
Dapsone 2 mg/mL in SyrSpend SF pH4 Oral Suspension	Vol. 21 No. 6	491
Fluconazole 10% in RECURA Cream	Vol. 21 No. 6	492
Haloperidol 5-mg/mL Injection	Vol. 21 No. 6	493
Hydroxychloroquine Sulfate 25 mg/mL in Oral Mix or Oral Mix SF	Vol. 21 No. 6	494
Promethazine Hydrochloride 12.5 mg/0.1 mL in PLO Gel	Vol. 21 No. 6	495
Spironolactone 5 mg/mL in SuspendIt Oral Suspension	Vol. 21 No. 6	496
Tolmetin 400-mg Capsules	Vol. 21 No. 6	497
Trace Elements Injection 5	Vol. 21 No. 6	498
Vancomycin 5-mg/mL Injection	Vol. 21 No. 6	499
To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid	Vol. 21 No. 6	500
Validation of the Technological Process of the Preparation "Milk by Vidal"	Vol. 21 No. 6	513
Auditing Safety of Compounding and Reconstituting of Intravenous Medicines on Hospital Wards in Finland	Vol. 21 No. 6	518
Effect of Penetration Enhancers on the Percuaneous Delivery of Hormone Replacement Actives	Vol. 21 No. 6	530